{rfName}
e1

Indexed in

License and use

Citations

3

Altmetrics

Analysis of institutional authors

Marce, SCorresponding AuthorXicoy, BAuthorCabezon, MAuthorSenin, AAuthorZamora, LAuthor
Share
Publications
>
Article

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Publicated to:Journal Of Clinical Medicine. 13 (3): 779- - 2024-02-01 13(3), DOI: 10.3390/jcm13030779

Authors: Marce, S; Mendez, A; Xicoy, B; Estrada, N; Cabezon, M; Sturla, AL; Garcia, MR; Angona, A; Amat, P; Serrat, SE; Scalzulli, E; Morgades, M; Senin, A; Hernandez-Boluda, JC; Ferrer-Marin, F; Anguita, E; Cortes, M; Plensa, E; Breccia, M; Garcia-Gutierrez, V; Zamora, L

Affiliations

Hosp Clin Univ INCLIVA Valencia, Hematol Dept - Author
Hosp Gen Granollers, Hematol Dept - Author
Hosp Gen Univ Morales Meseguer CIBERER, Hematol Dept, IMIB, UCAM - Author
Hosp Mataro, Consorci Sanitari Maresme, Consorci Sanit Maresme - Author
ICO Badalona Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst IJC, Myeloid Neoplasms Grp, Hematol Dept - Author
ICO Girona Hosp Josep Trueta, Hematol Dept - Author
ICO Hosp Hosp Duran y Reynals, Hematol Dept - Author
Sapienza Univ, Dept Precis & Translat Med, Policlin Umberto 1 - Author
Univ Alcalala Madrid, Hosp Ramon y Cajal, Hematol Dept, IRYCIS - Author
Univ Complutense Madrid UCM, Hosp Clin San Carlos, Hematol Dept, IML,IdISSC - Author
See more

Abstract

Keywords
Bcr::abl1 transcript typeChronic myeloid leukemiaDasatinibDiscontinuationImatinibNilotinibPrognostic discriminationRelapseRiskTherapyTreatment free remissionTyrosine kinase inhibitors

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Medicine due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 59/329, thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine, General & Internal.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-18:

  • Scopus: 3
  • OpenCitations: 2
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 10.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 10 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 7.05.
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Italy.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Marce Torra, Silvia) and Last Author (Zamora Plana, Lurdes).

the author responsible for correspondence tasks has been Marce Torra, Silvia.